Regeneron Pharmaceuticals (REGN) said Tuesday it will boost its American manufacturing footprint by partnering with Fujifilm Diosynth Biotechnologies to produce biologics at a new North Carolina site.
The long-term agreement grants Regeneron access to Fujifilm's recently built biopharma facility in Holly Springs, the company said, nearly doubling its current large-scale manufacturing volume in the US.
The project, set to begin with an immediate technology transfer, represents a total investment of more than $3 billion over ten years, Regeneron said.
Regeneron said it is advancing multiple initiatives in New York, including a $3.6 billion expansion in Tarrytown, a fill-and-finish plant in Rensselaer, and a newly acquired property in Saratoga Springs for future growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.